Hypercalcaemia in Patients with Disseminated Breast Cancer

Brada, Michael; Rowley, Mark; Grant, David J.W.; Ashley, S.; Powles, T. J.

doi:10.3109/02841869009090054

Cited by 11 publications

(10 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is in the range of what it has been published before the era of diphosphonates, when the median survival of CAH ranged from 30 to 90 days [2,7,8,[15][16][17]. There is no clear evidence that diphosphonate therapy improves outcome after CAH.…”

Section: Discussionmentioning

confidence: 54%

“…Hypercalcemia, defined as serum calcium superior to 2.60 mmol/l, is the most common metabolic disorder in patients with cancer [1][2]. Its incidence is estimated between 10 and 20% of all patients with cancer [1,2].…”

Section: Introductionmentioning

confidence: 99%

“…Its incidence is estimated between 10 and 20% of all patients with cancer [1,2]. Cancerassociated hypercalcemia (CAH) is either related to the paraneoplastic production of osteoclast-activating factor by cancer cells (humoral mediated hypercalcemia) or to the large direct osteoclastosis induced by cancer cells (local osteolytic hypercalcemia) [1].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Cancer-associated hypercalcemia treated with intravenous diphosphonates: a survival and prognostic factor analysis

Penel

Dewas

Doutrelant

et al. 2007

Support Care Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 54%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cancer-associated hypercalcemia treated with intravenous diphosphonates: a survival and prognostic factor analysis

Penel

Dewas

Doutrelant

et al. 2007

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…Our results indicated that ionized calcium cannot be used as a prognostic factor. These results agreed with Brada el al [46] and disagreed with Kristensen et al [47] as survival was found to be inversely associated with serum ionized calcium levels. It was found that elevated levels of phosphorus were necessary for adequate growth of some types of cancers [6], [7].…”

Section: Discussioncontrasting

confidence: 35%

The role of serum 25-hydroxyvitamin D, ionized calcium and phosphorus in breast cancer females: A case-control study

Moneim¹,

Hewala

Rashad³

et al. 2015

IJBAS

View full text Add to dashboard Cite

Aim: To evaluate the diagnostic and prognostic value of serum 25-hydroxyvitamin D (25(OH) D), ionized calcium and phosphorus in comparison with serum CA15.3 as the most commonly used breast cancer marker. Participants and methods: This study was conducted on 45 breast cancer female patients with recently detected breast cancer before surgery and 45 apparently healthy female controls of matched age, menstrual and socioeconomic status as breast cancer patients group. Serum 25(OH) D, ionized calcium, phosphorus and CA15.3 were measured using readyfor-use commercially available kits. Results: Serum levels of 25(OH) D and ionized calcium in the breast cancer patients group were significantly lower than those of the control group, while serum levels of phosphorus and CA15.3 in breast cancer patients group were significantly higher than those of the control group. The area under the ROC curve for serum ionized calcium (81.7%) was significantly greater than that of 25(OH) D (75.3%), CA 15.3 (70.1%) and phosphorus (62.8%). The odd's ratio of vitamin D was 0.0937 (95% CI=0.0311-0.2823), of ionized calcium was 0.0464 (95% CI=0.015-0.141) and of phosphorus was 2.6801(95% CI=1.1269-6.3742) in breast cancer patients group. Serum phosphorus was significantly correlated with age and menopausal status of breast cancer patients. Conclusion: Our results suggest that serum ionized calcium and 25(OH) D were superior to serum CA15.3 and phosphorus for prediction of breast cancer. In addition, our results indicate that 25 (OH) D and calcium may decrease the risk for breast cancer incidence, while phosphorus may increase this risk. None of the assayed biomarkers has a prognostic role in breast cancer.

show abstract

“…",'~ PTH-rp is secreted by most of the solid tumors of epithelial origin and, to a lesser degree in glandular tumors such as breast carcinoma. 12,16,17 The first 13 amino acids of PTH-rp have limited homology with PTH compared with that of different specie^. '^,'^ In addition to its effects on the bone, PTH-rp has a potent calcium-conserving effect on the renal tubule^.…”

mentioning

confidence: 99%

Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate

Wimalawansa

1994

Cancer

View full text Add to dashboard Cite

Background. Hypercalcemia of malignancy (HM) is one of the commonest metabolic complications associated with cancer. Plasma parathyroid hormone‐related peptide (PTH‐rp) is known to cause hypercalcemia in the vast majority of patients with HM. Methods. Fifty‐two patients with HM were treated with a single infusion of 60 mg of pamidronate (3‐amino‐1‐hydroxypropylidene‐1, 1‐bisphosphonate). Serum calcium and plasma PTH‐rp levels were measured at the basal and after pamidronate therapy. Results. Normocalcemia was achieved in 43 (i.e., 83%) of these patients within 3 to 5 days. Eighty‐one percent had increased plasma PTH‐rp levels. There was no difference in the percentages of patients who had elevated plasma PTH‐rp levels compared with those of patients with metastatic bone disease and humoral HM. However, the latter group of patients had significantly higher circulatory PTH‐rp levels (P < 0.01). The pretreatment calcium levels were not correlated with the calcium‐lowering responses nor with plasma PTH‐rp levels. However, there was a significant positive correlation between pretreatment plasma PTH‐rp levels and the nadir serum calcium (P < 0.001) and a negative correlation with the changes in serum calcium levels (P < 0.001) after pamidronate therapy. No relationship existed between pretreatment calcium levels or PTH‐rp levels with the extent or the severity of the metastatic bone disease. Patients who had the highest PTH‐rp levels had the worst prognosis, poorest calcium‐lowering effect, shortest duration of normocalcemia, and required higher doses and frequent infusions of pamidronate to maintain normocalcemia. The nonresponders to therapy had a significantly higher mean plasma PTH‐rp level (> 75 pg/ml) than the responders (P < 0.01). Conclusions. The plasma PTH‐rp levels may help to predict the calcium‐lowering effect of bisphosphonate and give an indication of the prognosis in patients with HM. They may allow identification of patients who need higher doses and increased frequency of administration of bisphosphonate, thereby expediting the normocalcemic response.

show abstract

Hypercalcaemia in Patients with Disseminated Breast Cancer

Cited by 11 publications

References 8 publications

Cancer-associated hypercalcemia treated with intravenous diphosphonates: a survival and prognostic factor analysis

Cancer-associated hypercalcemia treated with intravenous diphosphonates: a survival and prognostic factor analysis

The role of serum 25-hydroxyvitamin D, ionized calcium and phosphorus in breast cancer females: A case-control study

Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate

Contact Info

Product

Resources

About